High-level tumour methylation of BRCA1 and RAD51C is required for homologous recombination deficiency in solid cancers

Xu, L; Liddell, B; Nesic, K; Geissler, F; Ashwood, LM; Wakefield, MJ; Scott, CL; Waddell, N; Kondrashova, O

Author(s): Xu, L; Liddell, B; Nesic, K; Geissler, F; Ashwood, LM; Wakefield, MJ; Scott, CL; Waddell, N; Kondrashova, O;
Details: Publication Year 2024-09,Volume 6,Issue #3,Page zcae033
Journal Title: NAR Cancer
Abstract: In ovarian and breast cancer, promoter methylation of BRCA1 or RAD51C is a promising biomarker for PARP inhibitor response, as high levels lead to homologous recombination deficiency (HRD). Yet the extent and role of such methylation in other cancers is not clear. This study comprehensively investigated promoter methylation of eight homologous recombination repair genes across 23 solid cancer types. Here, we showed that BRCA1 methylated cancers were associated with reduced gene expression, loss of heterozygosity (LOH), TP53 mutations and genomic features of HRD. We identified BRCA1 methylation in 3% of the copy-number high subtype of endometrial cancer, and as a rare event in six other cancer types, including lung squamous cell, pancreatic, bladder and stomach cancer. RAD51C promoter methylation was widespread across multiple cancer types, but HRD features were only observed for cases which contained high-level tumour methylation and LOH of RAD51C. While RAD51C methylation was frequent in stomach adenocarcinoma (6%) and low-grade glioma (2.5%), it was mostly detected at a low tumour level, suggestive of heterozygous methylation, and was associated with CpG island methylator phenotype. Our findings indicate that high-level tumour methylation of BRCA1 and RAD51C should be explored as a PARP inhibitor biomarker across multiple cancers.
Publisher: Oxford Academic
Research Division(s): Bioinformatics; Cancer Biology And Stem Cells
PubMed ID: 39055334
Publisher's Version: https://doi.org/10.1093/narcan/zcae033
Open Access at Publisher's Site: https://doi.org/10.1093/narcan/zcae033
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-07-31 03:30:23

Last Modified: 2024-07-31 03:40:41